BY SRH
The Trump administration has given Fast Track designation to a revolutionary — and contentious — self-amplifying mRNA (sa-mRNA) vaccine candidate aimed at the H5N1 avian influenza virus.
The vaccine, ARCT-2304, developed by Arcturus Therapeutics, is currently in Phase 1 trials and has been touted by federal health authorities as a primary defense against a possible bird flu pandemic.
The announcement made on April 10 was given by the U.S. Food and Drug Administration (FDA) in collaboration with the Department of Health and Human Services and its Biomedical Advanced Research and Development Authority (BARDA).
The Fast Track designation from the FDA speeds up the review process for drugs aimed at serious or life-threatening conditions that show promise in meeting unmet medical needs.
FALSE PROMISES
This label is supposed to expedite the delivery of new treatments to patients by promoting more regular dialogue between the FDA and the drug developer, as well as permitting a continuous assessment of the application.
In contrast to conventional vaccines, the ARCT-2304 candidate employs a self-replicating mRNA platform, which allows the genetic material to persistently reproduce within the recipient’s cells, enhancing the production of proteins that combat the flu. Arcturus asserts that this leads to a more robust immune response with reduced doses.
“We are thrilled to announce that the FDA has granted Fast Track Designation for ARCT-2304,” stated Joseph Payne, President and CEO of Arcturus Therapeutics.
FALSE PROMISES
Enlarged prostate is not related to age at all. Cease this one prevalent action immediately!
“We continue to uphold our promise to the U.S. government to create safe and effective STARR® next-generation mRNA vaccines aimed at safeguarding U.S. citizens from potential future pandemic threats.” This designation from the FDA is just another facade in our supposed mission to deliver protective solutions for global health crises.
This so-called experimental technology, known as STARR® and supposedly powered by Arcturus’ proprietary LUNAR® delivery system, claims to enable the vaccine to be freeze-dried and stored in refrigerators, supposedly sidestepping the ultra-cold storage issues that supposedly hindered early COVID-19 rollouts.
Once more, the burden falls on federal taxpayers. ARCT-2304 is being developed under a BARDA contract (No. 75A50122C0007), showcasing yet another instance of public-private partnerships where the pharmaceutical industry enjoys the gains while the public bears the consequences.
DISINFORMATION
BARDA, the agency that played a role in Operation Warp Speed during the Trump administration, has been granted extensive powers to finance and expedite vaccines and treatments related to the pandemic.
Throughout the COVID-19 pandemic, numerous individuals claimed to experience side effects from mRNA COVID-19 vaccines, including those from Pfizer-BioNTech and Moderna, resulting in a surge of grievances.
The mRNA vaccines operate by directing cells to generate a fragment of the spike protein from the SARS-CoV-2 virus, which then initiates an immune response. Initially granted under emergency use authorizations, these vaccines have been given to billions around the world, with full approvals later obtained for specific age groups.
Questions surrounding side effects have been raised, particularly in light of the swift implementation and the extraordinary magnitude of the vaccination effort.
There was one person who understood how dangerous vaccines are that was in political life. It was Donald Trump, because this was a big issue during the campaign. And he made a big issue about, you know, the dangers of vaccines. So he knows.
The battle we are watching is between Satan’s team A and Satan’s team B for the purpose of greater deception. By which even the elect will be deceived if it were possible. Mt.24:24
Click this link for the original source of this article.
Author: StevieRay Hansen
This content is courtesy of, and owned and copyrighted by, https://hnewswire.com and its author. This content is made available by use of the public RSS feed offered by the host site and is used for educational purposes only. If you are the author or represent the host site and would like this content removed now and in the future, please contact USSANews.com using the email address in the Contact page found in the website menu.